store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
WP1066 是一种新型JAK2和STAT3抑制剂,对 STAT5 和 ERK1/2 也起作用。它用于研究黑色素瘤、脑癌、实体瘤和中枢神经系统肿瘤治疗。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 172 | 现货 | ||
5 mg | ¥ 378 | 现货 | ||
10 mg | ¥ 672 | 现货 | ||
25 mg | ¥ 1,330 | 现货 | ||
50 mg | ¥ 2,570 | 现货 | ||
100 mg | ¥ 3,780 | 现货 | ||
500 mg | ¥ 7,950 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 418 | 现货 |
产品描述 | WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3. WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central Nervous System Neoplasms. |
靶点活性 | JAK2:2.3 μM, STAT3:2.43 μM |
体外活性 | WP1066能剂量依赖性地显著抑制携带JAK2 V617F突变亚型的HEL细胞的生长(IC20/IC50/IC80:0.8/2.3/3.8 μM)。在表达JAK2 V617F突变亚型的急性白血病HEL细胞中,WP1066(0.5-4.0 μM)可抑制JAK2, STAT3, STAT5及ERK1/2的磷酸化,但对JAK1和JAK3的磷酸化无抑制作用。WP1066(0.5-3.0 μM),以剂量依赖性地抑制从病人体内获得的AML形细胞以及AML细胞系OCIM2和K562的增殖。浓度在0.5, 1.0, 2.0, 3.0或4.0 μM时的WP1066在OCIM2和K562细胞中,剂量依赖地降低JAK2和pJAK2的蛋白水平,同时STAT3,STAT5和AKT的磷酸化水平。WP1066(1,2或3 μM)可激活procaspase-3,裂开的PARP,剂量依赖地引起OCIM2和K562细胞的细胞凋亡。通过诱导处在细胞周期G0-G1期细胞的积累,WP1066(2 μM)可抑制OCIM2细胞增加。WP1066(5 μM)可阻止STAT3磷酸化,2.5 μM时能使Caki-1和 786-O肾癌细胞的生存和增殖受到显著抑制。 WP1066(5 μM)还能抑制Caki-1和786-O肾癌细胞中HIF1α和HIF2α的表达及VEGF的产生。 |
体内活性 | 在Caki-1移植小鼠中,连续服用19天WP1066(40 mg/kg/day,p.o.)可显著抑制的肿瘤生长,同时减少磷酸化的STAT3免疫染色,并降低CD34阳性血管长度. |
细胞实验 | The 3, [4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium (MTT) assay is done using an MTT-based cell proliferation/cytotoxicity assay system. Briefly, fresh low-density peripheral blood cells and various cell lines at the logarithmic phase of their growth are washed twice in RPMI 1640 containing 10% FCS and counted in a hemocytometer. Cell viability is assessed by the trypan blue (0.1%) staining method. Equal numbers of viable cells (5 × 104 per well) are incubated in a total volume of 100 μL of RPMI 1640 supplemented with 10% FCS alone or with WP1066 at increasing concentrations; the incubations are continued for up to 72 h in 96-well flat-bottomed plates at 37 °C in a humidified 5% CO2 atmosphere. Experiments for each condition are done in triplicate. After incubation, 20 μL of CellTiter96 One Solution Reagent are added to each well. The plates are then incubated for an additional 60 min at 37 °C in a humidified 5% CO2 atmosphere. Immediately after incubation, absorbance is read using a 96-well plate reader at a wavelength of 490 nm.(Only for Reference) |
分子量 | 356.22 |
分子式 | C17H14BrN3O |
CAS No. | 857064-38-1 |
store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 66 mg/mL (185.3 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8073 mL | 14.0363 mL | 28.0725 mL | 70.1813 mL |
5 mM | 0.5615 mL | 2.8073 mL | 5.6145 mL | 14.0363 mL | |
10 mM | 0.2807 mL | 1.4036 mL | 2.8073 mL | 7.0181 mL | |
20 mM | 0.1404 mL | 0.7018 mL | 1.4036 mL | 3.5091 mL | |
50 mM | 0.0561 mL | 0.2807 mL | 0.5615 mL | 1.4036 mL | |
100 mM | 0.0281 mL | 0.1404 mL | 0.2807 mL | 0.7018 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
WP1066 857064-38-1 Angiogenesis Apoptosis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK STAT WP 1066 inhibit Inhibitor Janus kinase WP-1066 inhibitor